57.5 F
Laguna Hills
Monday, Mar 18, 2024
-Advertisement-

Peregrine Pharmaceuticals Shares Drop on Critical Story

Tustin-based drug developer Peregrine Pharmaceuticals Inc.’s stock plummeted today after a website published a critical story about its lead drug candidate.

Investors sent Peregrine shares down 17% in midday New York trading, to a market value of about $240 million.

Peregrine shares are still up some 132% since the start of 2012.

Seeking Alpha published a story today that asserted that clinical trial results for Peregrine’s bavituximab drug candidate – a big factor in Peregrine’s rise – are “overhyped” and “inconclusive.”

The report was written by an unidentified analyst using the name “Apsara Biotechnology Research” who said he had a short position in Peregrine.

Peregrine’s shares had been rising steadily in recent weeks on positive indicators from the company on bavituximab, its lead drug candidate.

Want more from the best local business newspaper in the country?

Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-